Revolution in
early diagnostics.

Detecting neurodegenerative diseases such as Alzheimer’s, Parkinson’s or ALS up
to 17 years before the first symptoms appear? This is what we are working on with betaSENSE’s
innovative protein detection. Easy, clear, successful. Making independence in
old age a matter of course.

Timely diagnosis enables early treatment

When neurodegenerative diseases develop, the structure of certain biomarker proteins in body fluids changes. betaSENSE’s platform technology detects these alterations, known as misfoldings, in relevant proteins, using just a few drops of body fluid. This means an international breakthrough in the detection of neurodegenerative diseases – and clears the way for timely action.

Straightforward test provides certainty

Small amounts of body fluids are sufficient to assess the risk of developing Alzheimer’s disease,
Parkinson’s disease or ALS with the help of betaSENSE’s technology.

Science as the key to progress

With the betaSENSE method, we reduce research results to practice. The development of our platform technology is ground-breaking for cutting-edge research in the field of detecting neurodegenerative diseases.

Beacon for prevention and therapy
We want to enable affected persons to get prevention and targeted therapy. For early diagnosis means that the progression of the disease can be successfully influenced with drugs.

This is betaSENSE.

We aspire to revolutionise protein diagnostics. Our goal is the early detection of
neurodegenerative diseases. The basis for this is our innovative platform

Our scientific publications.

Alzheimer’s & Dementia, 2022

Alzheimer’s & Dementia, 2022

Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years
Go to article

Annals of Clinical & Translational Neurology, 2021

Annals of Clinical & Translational Neurology, 2021

TDP-43 as structure-based biomarker in amyotrophic lateral sclerosis
Go to article

Alzheimer’s Research & Therapy, 2020

Alzheimer’s Research & Therapy, 2020

Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
Go to article

at betaSENSE.

Join the diagnostics revolution. Our team consists of around 50 employees with expertise in various scientific disciplines. We are united by a pioneering spirit, combined with the desire to combat neurodegenerative diseases such as Alzheimer’s, Parkinson’s or ALS at an early stage.